

Clinical Investigation

Same-Day Carotid Artery Stenting and Coronary Artery Bypass Surgery

Igor Zivkovic, MD¹; Stasa Krasic, MD²; Petar Milacic, MD, PhD^{1,3}; Miroslav Milicic, MD, PhD^{1,3}; Petar Vukovic, MD, PhD^{1,3}; Zoran Tabakovic, MD¹; Dragan Sagic, MD, PhD^{3,4}; Nenad Ilijevski, MD, PhD^{3,5}; Ivana Petrovic, MD, PhD¹; Miodrag Peric, MD, PhD^{1,3}; Milovan Bojic, MD, PhD¹; Slobodan Micovic, MD, PhD^{1,3}

¹Department of Cardiac Surgery, Dedinje Cardiovascular Institute, Belgrade, Serbia

²Cardiology Department, Mother and Child Health Institute of Serbia, Belgrade, Serbia

³School of Medicine, University of Belgrade, Belgrade, Serbia

⁴Department of Interventional Radiology, Dedinje Cardiovascular Institute, Belgrade, Serbia

⁵Department of Vascular Surgery, Dedinje Cardiovascular Institute, Belgrade, Serbia

Abstract

Background: The optimal treatment strategy for patients with severe carotid artery disease undergoing coronary artery bypass grafting is still problematic. The important question is whether it is necessary to treat significant carotid disease in patients who have undergone coronary artery bypass grafting. This study analyzed short- and midterm results after same-day carotid artery stenting and coronary artery bypass grafting.

Methods: From 2013 to 2020, a total of 69 patients were enrolled in the study. Same-day carotid artery stenting and coronary artery bypass grafting were performed in all patients. The study's primary end points were the evaluation rate of stroke, myocardial infarction, and death within short- and midterm periods after the procedures.

Results: The 30-day mortality was 0%. The occurrences of perioperative adverse events, namely stroke, myocardial infarction, and transient ischemic attack, were 1 (1.4%), 1 (1.4%), and 4 (5.8%), respectively. Mean (IQR) follow-up time was 28 (IQR, 17-43) months. Six (8.8%) patients died during this period. Fatal stroke was registered in 2 cases, and 1 patient experienced a disabling stroke with a fatal outcome. The other 3 patients died because of chronic renal disease, a traffic accident, and for an unknown reason, respectively. Midterm survival in the group was 91.2%.

Conclusion: The study showed that same-day carotid artery stenting and coronary artery bypass grafting for concomitant carotid and coronary disease treatment could be a promising and feasible therapeutic strategy.

Keywords: Coronary disease; carotid disease; coronary artery bypass grafting surgery; carotid artery stenting; Lyme carditis; complete heart block; right bundle branch block

Introduction

Coronary artery disease (CAD) and carotid disease (CD) represent roughly 75% of all cardiovascular diseases. Approximately 10% (range, 4%-20%) of patients with proven CAD have significant CD, whereas 30% to 50% of patients with proven CD have significant CAD.¹

Transient ischemic attack (TIA), reversible ischemic neurological deficit, and/or cerebrovascular insult represent some of the most frequent and most severe complications that occur during coronary artery bypass grafting surgery (CABG).² It is reported in 0% to 2% of cases (average, 1.7%). However, the incidence of cerebral adverse events is much higher in the presence of carotid artery (CA) disease (2%-4%) if one CA is stenotic, 4% to 8% for both carotids, and even 18% if 1 carotid is occluded and the other is stenotic.^{2,3}

The etiology of perioperative stroke is multifactorial. Cerebrovascular events were caused by subsequent hypoperfusion resulting from embolic particles from the ascending aorta, CA, and bubbles of gaseous or cerebral hypoperfu-

Citation: Zivkovic I, Krasic S, Milacic P, Milicic M, Vukovic P, Tabakovic Z, Sagic D, Ilijevski N, Petrovic I, Peric M, Bojic M, Micovic S. Same-day carotid artery stenting and coronary artery bypass surgery. *Tex Heart Inst J*. 2023;50(1):e217781. doi:10.14503/THIJ-21-7781

Corresponding author: Igor Zivkovic, MD, Department of Cardiac Surgery, Dedinje Cardiovascular Institute, Heroja Milana Tepica 1, 11000 Belgrade, Serbia (igor88zivkovic@gmail.com)

© 2023 by The Texas Heart® Institute, Houston

sion during and after the cardiac procedure.^{4,5} Patients with substantial CA disease are at high risk for periprocedural cerebral events.⁶ Transient ischemic attack and the preoperative history of stroke have been associated with a 4-fold increased risk of postoperative events.^{3,7} Even if CA disease is present but asymptomatic, patients had a high risk of perioperative stroke after CABG.⁸ During the last nearly 50 years, 2 main surgical options have been used in patients with these challenging conditions: a single-stage procedure or a double-stage procedure (either CABG followed by carotid endarterectomy [CEA], or vice versa).⁹⁻¹¹ Optimal management has been discussed in many studies, but the best strategy is still problematic. The better outcome was evident in the surgical revascularization in both symptomatic and asymptomatic CA disease compared with medical treatment.¹² Carotid intervention in asymptomatic patients with CA disease and concomitant coronary disease has been the most controversial issue over the past few years because the management strategy guidelines for this group of patients are still problematic.¹³ The data on the efficacy of CA stenting (CAS) in treating asymptomatic CA disease are limited.¹⁴

This study analyzed the risk of major adverse events (TIA, stroke, myocardial infarction [MI], and death) during the early and midterm follow-up periods after same-day CAS and CABG procedures in patients with significant coronary disease and concomitant CA disease.

Patients and Methods

Study Design

This is a prospective nonrandomized longitudinal single-center study conducted from January 2013 to December 2020. The local institutional ethics committee approved the study protocol, and all patients signed the informed consent form. The study included 69 consecutive patients who underwent same-day CABG and CAS procedures.

Inclusion criteria for the study were substantial multivessel CAD that indicated CABG, as well as concomitant severe CA stenosis suitable for carotid stenting procedures. Exclusion criteria for the study were significant heart valve disease, calcification of femoral or iliac arteries, redo procedures, and unfavorable angiographic lesion characteristics for CAS.

Preoperative Diagnostic Procedures

The heart team (cardiologist, cardiac and vascular surgeons, and radiologist) evaluated all study participants. A preoperative physical exam was performed on all patients. CA disease was determined by a history of cere-

Abbreviations and Acronyms

| | |
|--------|---|
| ACT | activated clotting time |
| CA | carotid artery |
| CABG | coronary artery bypass grafting |
| CAD | coronary artery disease |
| CAS | carotid artery stenting |
| CCA | common carotid artery |
| CD | carotid disease |
| CEA | carotid endarterectomy |
| CT | computed tomography |
| ICA | internal carotid artery |
| MI | myocardial infarction |
| NASCET | North American Symptomatic Carotid Endarterectomy Trial |
| TIA | transient ischemic attack. |

brovascular events or carotid bruit on the auscultatory exam. Patients were considered asymptomatic if they had no history of TIA or stroke 120 days before the procedure.

The angiologist performed a preoperative color duplex scan to evaluate CA stenoses, plaque characteristics, and carotid blood flow velocity.

According to the “2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery,”¹⁵ computed tomography (CT) angiography offers excellent sensitivity and specificity for detecting carotid stenosis. The CT angiography scans of all patients confirmed the degree of CA stenosis, characteristics of the carotid plaque, and anatomy of cerebral circulation. Stenoses were measured using the NASCET (North American Symptomatic Carotid Endarterectomy Trial) criteria.

The indication for carotid revascularization was a reduction of the artery diameter by more than 80% in asymptomatic patients or by more than 50% in symptomatic patients according to the NASCET criteria. In patients with bilateral CA disease, the severity and morphology of the plaque were used to choose which artery to treat. The radiologists gave final approval regarding the anatomical suitability for carotid stenting.

Unfavorable angiographic lesion characteristics for CAS were recorded and subdivided into “Access,” “Arch,” or “Target Vessel” groups. Unfavorable access characteristics were low bifurcation/short common carotid artery (CCA), tortuous CCA, diseased CCA, and diseased/occluded external CA.

Arch characteristics included severe arch calcification, significant disease at the origin of the great vessels, type III arch, and bovine arch (conjoint origin of left CCA and brachiocephalic trunk).

Target vessel diseases included pinhole stenosis, circumferential calcification of CA (more than two-thirds of the circumference of the vessel at the lesion site), angulated internal CA (ICA) origin, and angulated distal ICA.

Indication for the CABG procedure was conducted by coronary angiography examination. Significant coronary stenosis was defined as a 50% reduction lumen of the coronary artery or functional flow reserved test value less than 0.75 for borderline stenosis.

Echocardiography was performed in all patients to evaluate heart function (ejection fraction and myocardial contractility), heart valve function, and morphology of the heart and great vessels.

Interventions

CAS Procedure Protocol. Carotid artery stenting was performed in the catheterization laboratory under local anesthesia before cardiac procedures. Pre- and post-procedure neurological status was evaluated, with the aim to detect old and newly created cerebrovascular disturbances. All patients received 100 mg of aspirin starting 2 days before the procedure. The percutaneous transfemoral approach was used in the stenting procedure. Heparin was administered at a dose of 200 IU/kg. All patients used a distal cerebral protection device (Emboshield; Abbott Vascular). Stenoses were dilated before placement and final stent expansion. Xact (Abbott Vascular), Cristallo Ideale (Invatec), and Carotid WALLSTENT (Boston Scientific) balloon-expandable stents were deployed into CCAs. Carotid artery stenting procedures were considered successful if residual stenoses were 20% or less and if complications such as stroke or TIA did not occur. Patients were transferred to the cardiac surgery operating theatre within 1 hour of the stenting procedure's completion. During that period, patients received intravenous heparin via infusion pump according to the activated clotting time (ACT) value, which was measured hourly. The aim was to maintain ACT for around 200 seconds.

CABG Procedure Protocol. The CABG procedures were performed using the standard on-pump technique. The surgery was done under general heparinization 400 IU/kg (target ACT >480 seconds). The graft of choice was the internal mammary artery for left anterior descending artery bypass, and great saphenous vein grafts were used for other coronary target arteries. Standard ascending aorta cannulation and venous cannulation were performed, and cardiopulmonary bypass was performed with a standard nonpulsatile technique. A crystalloid or cold blood cardioplegia was used. After the intervention was complete and patients were weaned from the cardiopulmonary bypass, a complete heparin reversal

was conducted by infusing a full dose of protamine and antifibrinolytic agent (tranexamic acid).

Periprocedural Pharmacological Protocol. Dual antiplatelet therapy was administered soon after the procedure, provided chest tube bleeding was less than 50 mL for 3 consecutive hours. Six hours after the cardiac procedure, 300 mg of clopidogrel was given as a loading dose in the intensive care unit via nasogastric tube, followed by 75 mg/day for 1 year postoperatively. In the patients with increased chest tube drainage, the clopidogrel loading dose was postponed to 10 hours after the surgical procedure. A 100-mg/day dose of aspirin was started the first morning after the procedure and continued for the remainder of the patient's life.

End Points

The end points of this study were the evaluation of major adverse events (TIA, stroke, MI, and death) in the early and midterm after the CAS and CABG procedures. A TIA was confirmed if the duration of symptoms (numbness, confusion, trouble seeing, severe headache) lasted fewer than 24 hours. A neurologist evaluated all patients in the early postoperative period. In addition, neurological symptomatology was evaluated using a CA doppler or CT brain examination. If the neurological deficit entirely subsided within 24 hours, a CT scan was not performed. The stroke was defined as a new focal neurologic deficit that persisted longer than 24 hours, with acute or subacute ischemic brain lesions confirmed by CT examination.

Strokes were classified according to their location (ipsilateral or contralateral) and their consequences (fatal, disabling, and nondisabling). A stroke was considered fatal when it caused patient death. The primary characteristic of a disabling stroke was disability 6 months after hospital discharge (at least moderate disability, with the need for some help in daily affairs). A nondisabling stroke was characterized by, after 6 months, patients who, at most, had only slight disability that did not require them to seek assistance with daily affairs.

An MI diagnosis was based on electrocardiogram changes, new regional wall motion abnormality detected by transthoracic ultrasonography, and elevation of the cardio-specific enzymes (CK-MB that was 5 times the 99th percentile of the normal reference range and high-sensitivity troponin I level).

Follow-Up

Follow-up was performed by telephone interview. All patients were contacted.

Statistical Analysis

Basic (descriptive) statistics included mean values, SDs, medians, and interquartile ranges of the monitored parameters. The difference in the distribution of specific characteristics among the groups was discovered using the χ^2 or Fisher exact test. The normality of the distribution of numerical variables was examined by applying the Shapiro-Wilk and Kolmogorov-Smirnov tests. The comparison between the groups was made using the Student *t* test and Mann-Whitney test. Binominal logistic regression analysis was used to define the relationship between the dependent binary variable and independent variables. All statistical methods were significant if the *P* value was .05 or less. Statistical software SPSS 25.0 (IBM) for Windows 10 was used to process the data.

TABLE I. Preoperative Characteristics of Patients^a

| Characteristic | No. (N = 69) | % |
|-----------------------------|--------------|------|
| Male sex | 49 | 71 |
| Family history of CVD | 43 | 62.3 |
| Hypertension | 67 | 97.1 |
| Hypercholesterolemia | 55 | 79.7 |
| Renal insufficiency | 2 | 2.9 |
| History of TIA | 3 | 4.3 |
| History of stroke | 7 | 10.3 |
| Peripheral vascular disease | 10 | 14.5 |
| COPD | 9 | 13 |
| History of MI | 33 | 47.8 |
| STEMI | 8 | 11.6 |
| Diabetes mellitus | 31 | 44.9 |
| NYHA classification | | |
| Class I | 6 | 8.7 |
| Class II | 50 | 72.5 |
| Class III | 13 | 18.8 |
| Ejection fraction, % | | |
| <30 | 9 | 13 |
| 30-50 | 36 | 52.2 |
| >50 | 24 | 34.8 |

COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; MI, myocardial infarction; NYHA, New York Heart Association; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischemic attack.

^a Mean (SD) data are for continuous variables with normal distribution; median value and IQRs are for continuous variables with nonnormal distribution.

Results

The study included 69 patients (49 male, 20 female) with an average (SD) age of 65.3 (7.4) years. Preoperative cerebrovascular adverse events occurred in 14.6% of patients. The preoperative mean EuroSCORE II was 2.1 (IQR, 1.7-2.6). Other preoperative characteristics of the patients are reported in Table I. In 39.1% of patients, diffuse coronary disease was registered. The mean (SD) value of treated carotid stenosis was 84.4% (9.9%), and that of contralateral stenosis was 45.9% (25.3%). The internal CA peak systolic velocity was 320 (IQR, 270-440) cm/s, and the ICA end-diastolic velocity was 145 (IQR, 110-200) cm/s by Doppler velocity measurement. Additional diagnostic characteristics are presented in Table II. No postoperative revision was conducted because of bleeding. Intraoperative and perioperative characteristics are presented in Table III.

End Points

The 30-day rate of death was 0%. In 1 patient with severe bilateral asymptomatic CA disease, periprocedural ipsilateral stroke was registered. The reason for stroke was acute in-stent thrombosis, as revealed by CT and color duplex scan. In the same patient, because of perioperative MI and ventricular fibrillation, cardiopulmonary resuscitation was performed. This patient was

TABLE II. Diagnostic Characteristics of Patients

| | No. | % |
|--|-----|------|
| Coronary artery angiography | | |
| Three-vessel coronary disease | 60 | 87 |
| Left main disease | 17 | 24.6 |
| Diffuse coronary disease | 27 | 39.1 |
| CA disease | | |
| Degree of stenosis on treated CA (CT angiography), % | | |
| <60 | 0 | 0 |
| 60-69 | 2 | 2.9 |
| 70-79 | 13 | 18.8 |
| 80-89 | 30 | 43.5 |
| 90-99 | 24 | 34.8 |
| Degree of stenosis on untreated CA (CT angiography), % | | |
| <50 | 36 | 52.2 |
| 50-70 | 22 | 31.9 |
| 70-99 | 6 | 8.7 |
| 100 | 5 | 7.2 |

CA, carotid artery; CT, computed tomography.

discharged from the hospital after the recovery period. The rate of procedural TIA was 5.8%. In these patients, statistical analyses did not show a significant difference in the preoperative characteristics in compared groups. Patients with postoperative TIA were older than were the patients without TIA, at near statistical significance ($P = .07$). The cardiac procedure in patients with TIA was postponed for 30 days. The clinical outcomes within 30 days after revascularization are presented in Table IV.

Follow-Up

The mean (IQR) follow-up period was 28 (17-43) months. Six (8.8%) patients died during the follow-up period (Fig. 1). Two patients had a mortality stroke, and one had a massive disabling stroke with fatal complications. All patients who had a stroke had stenosis of 80% to 90%. The reasons for mortality in the other 3 cases were renal failure, a traffic accident, and an unknown cause. Hospitalization resulting from heart failure was registered in 1 case. The patients who died had a significantly lower ejection fraction than the rest of the group (32.5% [12.1%] vs 48.2% [10.17%]) ($P = .03$). Patient sex had no influence on the in-hospital and midterm mortality rate ($P = .999$) (Fig. 2), nor did it influence the occurrence of major events ($P = .999$).

TABLE III. Intraoperative and Perioperative Characteristics of Patients^a

| Characteristic | Value (N = 69) |
|---|----------------|
| CPB time, mean (SD), min | 76.9 (25.9) |
| Cross-clamp time, mean (SD), min | 53.7 (18.3) |
| No. of bypasses, median (IQR) | 2 (2-4) |
| Inotropic agents, No. (%) | 31 (44.9) |
| Chest tube drainage in 6 h, median (IQR), mL | 200 (100-300) |
| Chest tube drainage in 24 h, median (IQR), mL | 400 (300-575) |
| Ventilation time, mean (SD), h | 12.7 (3.9) |
| Revision because of bleeding, No. (%) | 3 (4.3) |
| Mental confusion, No. (%) | 8 (11.6) |
| Pleural effusion, No. (%) | 3 (4.3) |
| Atrial fibrillation, No. (%) | 19 (27.5) |
| Wound infection, No. (%) | 5 (7.2) |
| Mediastinitis, No. (%) | 0 (0) |
| ICU stay, median (IQR), d | 2 (1-3) |
| In-hospital stay, median (IQR), d | 7 (6-10) |

CPB, cardiopulmonary bypass; ICU, intensive care unit; IQR, interquartile range.

^a Mean (SD) data are for continuous variables with normal distribution; median value and IQRs are for continuous variables with nonnormal distribution.

Discussion

Perioperative stroke increased mortality in the open heart surgery population. This condition is multifactorial, caused by atheroembolic dislodgment from the ascending aorta during cannulation, debridement of calcified heart valves, aortic cross-clamping, and proximal anastomosis construction.⁸ The rate of perioperative stroke was about 2% in most patients who underwent CABG, but this rate reached 11% in high-risk patients with significant bilateral disease or contralateral occlusion of the carotid artery.^{3,16} Patients with asymptomatic severe CA disease had a 3% rate of periprocedural stroke, and stroke increased the mortality rate to 21%.^{4,17} Surgical coronary artery revascularization had better clinical results than medical treatment.¹² The 2 most common revascularization strategies are (1) CEA performed at the same time as CABG (simultaneous) or before the CABG procedure (staged) or (2) CAS performed simultaneously (hybrid) or staged with the CABG procedure.^{9,10}

The primary goal of this study was to explore the safety of the same-day strategy—CAS followed by CABG—in terms of (1) adverse neurological and/or cardiac events during CAS, (2) adverse neurological and/or cardiac events during CABG, (3) tendency for increased bleeding during CABG, and (4) 30-day rate of major cardiac and/or neurological events.

It was found that this strategy (same-day procedure, sequential CAS followed by CABG) is an acceptable alternative for the 1-stage procedure in a select group of patients.

More than 85% of patients undergo surgical revascularization in Western countries because of asymptomatic CA disease. In the study by Feldman et al,¹² which included 22,501 procedures, more than 96% of patients in the cohort underwent CEA and CABG for asymptomatic disease.

Current guidelines do not recommend routine preoperative screening for CD in those who have undergone cardiac surgery procedures.¹⁸

TABLE IV. Clinical Outcomes Within 30 Days of Hybrid Revascularization

| Major events | No. (N = 69) | % |
|------------------------------------|--------------|-----|
| Stroke | 1 | 1.4 |
| Transient ischemic attack | 4 | 5.8 |
| Myocardial infarction | 1 | 1.4 |
| Death | 0 | 0 |
| Death/stroke/myocardial infarction | 2 | 2.8 |




Fig. 1 Kaplan-Meier survival curve in patients who underwent same-day carotid artery stenting and coronary artery bypass surgery showed an 8.8% mortality rate during the follow-up period ($P < .05$).

The optimal treatment of combined carotid and heart disease remains controversial, especially in patients with asymptomatic CA disease.¹⁹ The decision to treat asymptomatic disease in the setting of the cardiac procedure was complex because cardiac intervention may be complicated by disease in other vascular beds, but there is no clear evidence of benefits for the treatment of asymptomatic carotid disease simultaneously with cardiac surgery.²⁰ Santarpino et al²¹ showed a low prevalence of perioperative stroke in patients with significant asymptomatic CA disease. Several studies presented a 2% to 4% perioperative stroke rate in a population of patients with untreated 50% to 99% unilateral and bilateral carotid stenosis.^{16,19,22} Naylor et al²³ claim that untreated unilateral carotid stenoses of 70% to 99% in populations who undergo open heart surgery did not increase the incidence of perioperative stroke (2%). A prospective multicentric observational study revealed a significant risk of perioperative stroke in patients with CA stenosis of more than 90%.²¹ The meta-analysis and systematic review analyzed the 30-day results of different revascularization strategies. In the synchronous CEA and CABG group, cumulative death rates and stroke were 8.2%, and composite outcomes (death, stroke, and MI) were 11.5%. This group had the highest rate of postoperative adverse events. The staged CEA and CABG showed better results than simultaneous surgery (6.1% and 10.2%, respectively).¹⁸ In the CAS and CABG group, rates of adverse outcomes reached 7.5% for death and stroke and 9.4% for composite outcomes.²³ These results show that staged procedures are generally associated with lower stroke and death rates than simultaneous ones.^{18,23} Van der Heyden et al²⁴ de-




Fig. 2 Kaplan-Meier survival curves for male and female patients who underwent same-day carotid artery stenting ($P < .05$).

scribed a satisfactory rate of combined death, stroke, and MI (6.7%) in the population of patients with asymptomatic CA disease who underwent staged CAS and CABG. Feldman et al¹² demonstrated that staged CAS and CABG were associated with a low risk of mortality; they claim that this approach could be a viable alternative to the surgical approach (CEA and CABG).²⁵

The first multicentric study (101 patients) published by Versaci et al¹⁰ presented 30-day clinical outcomes after the hybrid procedure (CAS and CABG); the rate of major postoperative adverse events was 4%. In this study, the rate of adverse composite outcomes was 2.8% in the 30 postoperative days. The aggregate efficacy/safety outcomes of adverse events during the postoperative period did not differ significantly between CAS and CEA procedures.¹⁶ A meta-analysis by Sardar et al¹⁴ revealed a higher incidence of minor (nondisabling) stroke in the CAS group than the CEA group, where MI was more common. The single-center study by Shishehbor et al²⁶ suggested that more interstage MI exists in the staged CEA and CABG group. The simultaneous revascularization using CAS and CABG is a feasible and promising therapeutic strategy, a statement confirmed by Versaci et al.¹⁰ Their claim was supported by Brott et al²⁷ in the guidelines on the management of patients with extracranial carotid and vertebral disease.

The literature described a minimal number of studies that presented results about patients with significant

carotid and coronary disease treated on the same day with simultaneous CAS and CABG.

This study evaluated this new strategy after collecting a reasonable number of patients over an acceptably long period. The reason why the number of patients indicated for this particular strategy was limited (69 patients) was because the decisive factor for indicating this approach was “durability of the carotid lesion,” a final decision that was made by the interventional radiologist. Many patients were selected to undergo either single- or double-stage surgical revascularization procedures during the same period. However, these “groups” are impossible to compare owing to the bias inherent in the decision-making process from the beginning. Because of this, randomized and prospective studies might be pretty problematic, even impossible, to design because of the following reasons: (1) institutions are rarely able to recruit enough patients over a reasonably short period, (2) criteria for randomization could be challenging to define, and (3) inconsistency might be a problem owing to the possibility of long-lasting studies.

The only realistic option for exploring this particular surgical strategy is to retrospectively analyze obtained results and eventually compare them with the results obtained at the same institution using another surgical strategy.

Study Limitations

The small sample size and single-center study were major limitations of this study. Future multicenter prospective randomized studies with a large number of participants are needed to confirm the benefit of this approach.

Conclusion

The results of this study confirmed the possibility of CAS being a safe and effective option for treating patients with concomitant carotid and coronary disease. Carotid artery stenting and CEA procedures should be complementary rather than competitive strategies that are used based on the individual characteristics of patients with concomitant disease. In these patients, a complex procedure that takes more time and is more logistically demanding should be replaced with a less-complicated one. The future prospective randomized study should additionally confirm this constation.

Published: 2 February 2023

Conflict of Interest Disclosures: None

Funding/Support: None

References

1. Zivkovic I, Vukovic P, Milacic P, et al. Midterm results after simultaneous carotid artery stenting and cardiac surgery. *Ann Thorac Surg*. 2020;110(5):1557-1563. doi:10.1016/j.athoracsur.2020.02.051
2. Nijs K, Vandenbrande J, Vaqueriza F, et al. Neurological outcome after minimal invasive coronary artery surgery (NOMICS): protocol for an observational prospective cohort study. *BMJ Open*. 2017;7(10):e017823. doi:10.1136/bmjopen-2017-017823
3. Habib N, Mahmoodi BK, Suttorp MJ, et al. Long-term results of carotid stenting and risk factors in patients with severe carotid artery stenosis undergoing subsequent cardiac surgery. *Catheter Cardiovasc Interv*. 2019;93(3):E134-E139. doi:10.1002/ccd.27947
4. Giannopoulos S, Texakalidis P, Charisis N, et al. Synchronous carotid endarterectomy and coronary artery bypass graft versus staged carotid artery stenting and coronary artery bypass graft for patients with concomitant severe coronary and carotid stenosis: a systematic review and meta-analysis. *Ann Vasc Surg*. 2020;62:463-473.e4. doi:10.1016/j.avsg.2019.06.018
5. Kapetanakis EI, Stamou SC, Dullum MK, et al. The impact of aortic manipulation on neurologic outcomes after coronary artery bypass surgery: a risk-adjusted study. *Ann Thorac Surg*. 2004;78(5):1564-1571. doi:10.1016/j.athoracsur.2004.05.019
6. Chiariello L, Nardi P, Pellegrino A, et al. Simultaneous carotid artery stenting and heart surgery: expanded experience of hybrid surgical procedures. *Ann Thorac Surg*. 2015;99(4):1291-1297. doi:10.1016/j.athoracsur.2014.11.043
7. Naylor AR, Mehta Z, Rothwell PM, Bell PRF. Reprinted article “Carotid artery disease and stroke during coronary artery bypass: a critical review of the literature.” *Eur J Vasc Endovasc Surg*. 2011;42(suppl 1):S73-S83.
8. Dong H, Che W, Jiang X, et al. Carotid artery stenting followed by open heart surgery in 323 patients: one-year results and influencing factors. *Catheter Cardiovasc Interv*. 2018;91(S1):632-638. doi:10.1002/ccd.27486
9. Velissaris I, Kiskinis D, Anastasiadis K. Synchronous carotid artery stenting and open heart surgery. *J Vasc Surg*. 2011;53(5):1237-1241. doi:10.1016/j.jvs.2010.11.049
10. Versaci F, Reimers B, Del Giudice C, et al. Simultaneous hybrid revascularization by carotid stenting and coronary artery bypass grafting: the SHARP study. *JACC Cardiovasc Interv*. 2009;2(5):393-401. doi:10.1016/j.jcin.2009.02.010
11. Rosenfield K, Matsumura JS, Chaturvedi S, et al. Randomized trial of stent versus surgery for asymptomatic carotid stenosis. *N Engl J Med*. 2016;374(11):1011-1020. doi:10.1056/NEJMoa1515706
12. Feldman DN, Swaminathan RV, Geleris JD, et al. Comparison of trends and in-hospital outcomes of concurrent carotid artery revascularization and coronary artery bypass graft surgery: the United States experience 2004 to 2012. *JACC Cardiovasc Interv*. 2017;10(3):286-298. doi:10.1016/j.jcin.2016.11.032
13. Sharma V, Deo SV, Park SJ, Joyce LD. Meta-analysis of staged versus combined carotid endarterectomy and coronary artery bypass grafting. *Ann Thorac Surg*. 2014;97(1):102-109. doi:10.1016/j.athoracsur.2013.07.091
14. Sardar P, Chatterjee S, Aronow HD, et al. Carotid artery stenting versus endarterectomy for stroke prevention: a meta-analysis of clinical trials. *J Am Coll Cardiol*. 2017;69(18):2266-2275. doi:10.1016/j.jacc.2017.02.053

15. Aboyans V, Ricco JB, Bartelink MLEL, et al; ESC Scientific Document Group. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European Stroke Organization (ESO), the Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J*. 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095
16. Gurm HS, Yadav JS, Fayad P, et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. *N Engl J Med*. 2008;358(15):1572-1579. doi:10.1056/NEJMoa0708028
17. Cook DJ, Huston J III, Trenerry MR, Brown RD Jr, Zehr KJ, Sundt TM III. Postcardiac surgical cognitive impairment in the aged using diffusion-weighted magnetic resonance imaging. *Ann Thorac Surg*. 2007;83(4):1389-1395. doi:10.1016/j.athoracsur.2006.11.089
18. Naylor AR, Bown MJ. Stroke after cardiac surgery and its association with asymptomatic carotid artery disease: an updated systematic review and meta-analysis. *Eur J Vasc Surg*. 2011;41(5):607-624. doi:10.1016/j.ejvs.2011.02.016
19. Weimar C, Billilis K, Rekowski J, et al. Safety of simultaneous coronary artery bypass grafting and carotid endarterectomy versus isolated coronary artery bypass grafting: a randomized clinical trial. *Stroke*. 2017;48(10):2769-2775. doi:10.1161/STROKEAHA.117.017570
20. Gottesman RF. Asymptomatic carotid stenosis in cardiac surgery patients: is less more? *Stroke*. 2017;48(10):2650-2651. doi:10.1161/STROKEAHA.117.018754
21. Santarpino G, Nicolini F, De Feo M, et al. Prognostic impact of asymptomatic carotid artery stenosis in patients undergoing coronary artery bypass grafting. *Eur J Vasc Endovasc Surg*. 2018;56(5):741-748. doi:10.1016/j.ejvs.2018.07.042
22. Baiou D, Karageorge A, Spyt T, Naylor AR. Patients undergoing cardiac surgery with asymptomatic unilateral carotid stenoses have a low risk of peri-operative stroke. *Eur J Vasc Endovasc Surg*. 2009;38(5):556-559. doi:10.1016/j.ejvs.2009.08.001
23. Naylor AR, Mehta Z, Rothwell PM. A systematic review and meta-analysis of 30-day outcomes following staged carotid artery stenting and coronary bypass. *Eur J Vasc Endovasc Surg*. 2009;37(4):379-387. doi:10.1016/j.ejvs.2008.12.011
24. Van der Heyden J, Suttorp MJ, Bal ET, et al. Staged carotid angioplasty and stenting followed by cardiac surgery in patients with severe asymptomatic carotid artery stenosis: early and long-term results. *Circulation*. 2007;116(18):2036-2042. doi:10.1161/CIRCULATIONAHA.106.658625
25. Barrera JG, Rojas KE, Balestrini C, et al. Early results after synchronous carotid stent placement and coronary artery bypass graft in patients with asymptomatic carotid stenosis. *J Vasc Surg*. 2013;57(suppl 2):58S-63S. doi:10.1016/j.jvs.2012.06.116
26. Shishehbor MH, Venkatachalam S, Sun Z, et al. A direct comparison of early and late outcomes with three approaches to carotid revascularization and open heart surgery. *J Am Coll Cardiol*. 2013;62(21):1948-1956. doi:10.1016/j.jacc.2013.03.094
27. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. *J Am Coll Cardiol*. 2011;57(8):1002-1044. doi:10.1016/j.jacc.2010.11.005